Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Fibromun + doxorubicin versus doxorubicin alone in first-line advanced soft tissue sarcoma
2024-512789-32-00Phase 3Authorised
- Sponsor
- Philogen
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing Fibromun + doxorubicin with Doxorubicin alone (2 arms). Primary endpoint: Progression-free survival. Planned start May 2024; status: authorised.
02
Drugs
onfekafusp alfadoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-512789-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512789-32-00.